In a quiet lab at Nara Medical University, a medical experiment is underway that could transform how we treat trauma, surgery, childbirth—and even prepare for the next global crisis. Scientists are injecting volunteers with artificial blood. It’s not just synthetic—it’s universal. No blood type. No virus risk. No need for a donor.
Made from expired human blood, stripped down to pure hemoglobin and encased in a stable shell, these lab-grown red cells—known as hemoglobin vesicles—are designed to carry oxygen like the real thing. But unlike traditional transfusions, they don’t need to be refrigerated within 42 days or matched to a recipient’s blood type. They can be stored for years, used in anyone, anywhere.
If it sounds like science fiction, it isn’t. In March 2025, researchers began administering doses of up to 400 milliliters to healthy volunteers. So far, the side effects have been mild. The implications? Massive.
Artificial Blood From Japan Doesn’t Need a Type—or Even a Fridge
The artificial blood, developed by Professor Hiromi Sakai’s team, is made by extracting hemoglobin from expired donor blood and encapsulating it in lipid shells. These vesicles mimic natural red blood cells and carry oxygen—but without blood type markers, making them universally compatible and virus-free.
Unlike donated blood, which needs to be refrigerated and expires within 42 days, this artificial version can last up to two years at room temperature and five years refrigerated. That makes it not only more accessible but also a potential game changer for emergency stockpiles, humanitarian crises, and remote regions with little to no blood donation infrastructure.
See also: A New COVID Variant Is Surging in China—and It’s Already in the U.S.
So… They’re Putting It in People Now?
Yes. After small-scale safety trials began in 2022, researchers moved forward in March 2025, injecting up to 400 milliliters of the lab-grown blood into healthy volunteers aged 20 to 50. While a few participants experienced minor side effects like fever or rash, none showed alarming shifts in blood pressure or vital signs.
The next phase will test efficacy: how well the synthetic cells carry oxygen and perform under stress. If successful, Sakai’s team hopes to push the product into clinical use by 2030.
Meanwhile, other scientists—like Professor Teruyuki Komatsu at Chuo University—are developing alternative artificial oxygen carriers using different stabilizing proteins. All signs point toward a future where synthetic blood isn’t just possible, but essential.
Why This Actually Matters
According to the World Health Organization, 40% of all blood donations come from high-income countries, which only make up 16% of the global population. That means billions of people live in places where safe transfusions are far from guaranteed.
Artificial blood could eliminate deadly delays in treatment during childbirth, trauma, surgery, or war. It also offers a way to overcome the immunological complications, viral risks, and shelf-life limits of donor blood—particularly in countries where blood banking is inconsistent or under-resourced.
This isn’t just a scientific novelty. It’s a public health intervention with the potential to reduce preventable deaths by the millions.
See also: Trump Administration Just Limited Access to COVID Vaccines—Do You Still Qualify?
The Science Fiction Is Getting Real
Of course, this isn’t the first time scientists have tried to crack the artificial blood code. Past attempts in the U.S. and U.K. have faced serious setbacks, especially around safety and reliability. But Japan’s approach—recycling expired human blood, stabilizing it, and skipping blood type compatibility—might be the practical solution medicine has been chasing for decades.
Still, the tech isn’t perfect. Since it relies on hemoglobin extracted from real blood, it’s not fully synthetic—or scalable without donor sources. Researchers believe recombinant hemoglobin or plant-based systems might be next. For now, this version is a bridge. But it’s a strong one.
What Happens Next?
If larger trials confirm both safety and effectiveness, Japan’s artificial blood could start showing up in ambulances, field hospitals, and operating rooms within the next five years. It could also be a literal lifeline in conflict zones or disaster areas, where getting a compatible, safe blood transfusion is next to impossible.
The dream isn’t immortality or super-soldiers. It’s something far more urgent: equity. A world where your blood type—or your proximity to a hospital—doesn’t determine whether you survive.
